GLP-1 and AFib: What Heart Patients Need to Know

What the cardiovascular trials actually show

The large outcome trials — SUSTAIN-6, LEADER, SELECT — established GLP-1s as cardioprotective: they reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in high-risk patients. Atrial fibrillation was not a signal of harm in these trials; if anything, the metabolic improvements from weight loss point the other direction. Obesity is an established AFib risk factor — epicardial fat directly promotes atrial electrical instability.

The heart-rate caveat

GLP-1s modestly increase resting heart rate — typically 2-4 beats per minute — a documented, usually benign effect. For most patients this is imperceptible. For AFib patients on rate-control therapy (beta-blockers, calcium channel blockers, digoxin), it is relevant enough that your cardiologist should know you are starting — dose interactions and monitoring are their call to make.

Palpitations on GLP-1s: usually not AFib

Many patients report racing or fluttering sensations during GLP-1 titration — and most of it is not AFib. The more likely culprits are dehydration (the most common GLP-1 side effect chain), reduced caloric intake, anxiety around a new medication, and caffeine changes. But a new irregular rhythm is a check-the-rhythm event, not a probably-fine event — especially with known AFib history. See our GLP-1 and palpitations guide and GLP-1 heart health overview.

Frequently asked questions

Is Ozempic safe if you have atrial fibrillation?

Generally yes, with cardiologist awareness. Major cardiovascular outcome trials (SUSTAIN-6, SELECT, others) showed GLP-1s are cardioprotective overall — reducing major cardiac events. AFib itself is not a contraindication. The caveat: GLP-1s raise resting heart rate slightly (2-4 bpm), which matters for some AFib patients.

Do GLP-1s cause AFib or make it worse?

No evidence links GLP-1s to new-onset AFib or worsening episodes. If anything, weight loss and improved metabolic health may reduce AFib burden — obesity is an established AFib risk factor. Palpitations during titration are usually dehydration or anxiety, not AFib.

Why does my heart race on Ozempic?

GLP-1s modestly raise resting heart rate (2-4 bpm average) as a known effect — usually imperceptible and benign. But dehydration, reduced food intake, anxiety, and caffeine changes also cause racing sensations. Persistent racing or irregular rhythm deserves a check, not an assumption.

Should I tell my cardiologist before starting GLP-1s with AFib?

Yes — absolutely. Your cardiologist should know because: resting HR changes may interact with rate-control drugs (beta-blockers, digoxin), weight loss can reduce AFib medication needs over time, and anticoagulation monitoring (warfarin) can shift with major dietary change.

Can weight loss from GLP-1s improve AFib?

Possibly — obesity is a modifiable AFib risk factor, and substantial weight loss is associated with reduced AFib episode frequency and better ablation outcomes in studies. GLP-1-driven weight loss may deliver this benefit, though dedicated AFib outcome trials are pending.

Bottom line

AFib and GLP-1s can coexist — the heart-trial evidence is genuinely reassuring — but this is a "tell your cardiologist" situation, not a "figure it out alone" one. The resting HR change and anticoagulation interactions are manageable with awareness; obesity itself is the bigger AFib driver that the medication may actually help.